Benzinga's Top #PreMarket Gainers

shares rose 33.03 percent to $10.23 in pre-market trading after the company agreed to be acquired by Skyworks Solutions Inc

for $10.50 per share.

gained 14.34 percent to $21.37 in pre-market trading after the company reported that the FDA has approved Optune in combination with temozolomide for treatment of newly diagnosed glioblastoma.

shares climbed 6.78 percent to $6.30 in pre-market trading after the company reported positive overall survival results from coBRIM phase 3 pivotal trial.

shares rose 5.79 percent to $54.25 in pre-market trading after the company reported that its CEO Ellen Kullman is stepping down.

shares rose 2.76 percent to $98.45 in pre-market trading after the company reported better-than-expected results for its third quarter.